BACKGROUND/AIMS: Mindfulness-based stress reduction (MBSR) has enhanced cognition, positive emotion, and immunity in younger and middle-aged samples; its benefits are less well known for older persons. Here we report on a randomized controlled trial of MBSR for older adults and its effects on executive function, left frontal asymmetry of the EEG alpha band, and antibody response. METHODS:Older adults (n = 201) were randomized to MBSR or waiting list control. The outcome measures were: the Trail Making Test part B/A (Trails B/A) ratio, a measure of executive function; changes in left frontal alpha asymmetry, an indicator of positive emotions or approach motivation; depression, mindfulness, and perceived stress scores, and the immunoglobulin G response to a protein antigen, a measure of adaptive immunity. RESULTS:MBSR participants had a lower Trails B/A ratio immediately after intervention (p < 0.05); reduced shift to rightward frontal alpha activation after intervention (p = 0.03); higher baseline antibody levels after intervention (p < 0.01), but lower antibody responses 24 weeks after antigen challenge (p < 0.04), and improved mindfulness after intervention (p = 0.023) and at 21 weeks of follow-up (p = 0.006). CONCLUSIONS:MBSR produced small but significant changes in executive function, mindfulness, and sustained left frontal alpha asymmetry. The antibody findings at follow-up were unexpected. Further study of the effects of MBSR on immune function should assess changes in antibody responses in comparison to T-cell-mediated effector functions, which decline as a function of age.
RCT Entities:
BACKGROUND/AIMS: Mindfulness-based stress reduction (MBSR) has enhanced cognition, positive emotion, and immunity in younger and middle-aged samples; its benefits are less well known for older persons. Here we report on a randomized controlled trial of MBSR for older adults and its effects on executive function, left frontal asymmetry of the EEG alpha band, and antibody response. METHODS: Older adults (n = 201) were randomized to MBSR or waiting list control. The outcome measures were: the Trail Making Test part B/A (Trails B/A) ratio, a measure of executive function; changes in left frontal alpha asymmetry, an indicator of positive emotions or approach motivation; depression, mindfulness, and perceived stress scores, and the immunoglobulin G response to a protein antigen, a measure of adaptive immunity. RESULTS: MBSR participants had a lower Trails B/A ratio immediately after intervention (p < 0.05); reduced shift to rightward frontal alpha activation after intervention (p = 0.03); higher baseline antibody levels after intervention (p < 0.01), but lower antibody responses 24 weeks after antigen challenge (p < 0.04), and improved mindfulness after intervention (p = 0.023) and at 21 weeks of follow-up (p = 0.006). CONCLUSIONS: MBSR produced small but significant changes in executive function, mindfulness, and sustained left frontal alpha asymmetry. The antibody findings at follow-up were unexpected. Further study of the effects of MBSR on immune function should assess changes in antibody responses in comparison to T-cell-mediated effector functions, which decline as a function of age.
Authors: Min Wang; Nao J Gamo; Yang Yang; Lu E Jin; Xiao-Jing Wang; Mark Laubach; James A Mazer; Daeyeol Lee; Amy F T Arnsten Journal: Nature Date: 2011-07-27 Impact factor: 49.962
Authors: Sanae Sasaki; Xiao-Song He; Tyson H Holmes; Cornelia L Dekker; George W Kemble; Ann M Arvin; Harry B Greenberg Journal: PLoS One Date: 2008-08-20 Impact factor: 3.240
Authors: Ayla Kruis; Heleen A Slagter; David R W Bachhuber; Richard J Davidson; Antoine Lutz Journal: Psychophysiology Date: 2016-02-12 Impact factor: 4.016
Authors: Blake T Gurfein; Olga Davidenko; Mary Premenko-Lanier; Jeffrey M Milush; Michael Acree; Mary F Dallman; Chadi Touma; Rupert Palme; Vanessa A York; Gilles Fromentin; Nicolas Darcel; Douglas F Nixon; Frederick M Hecht Journal: Mol Med Date: 2014-04-22 Impact factor: 6.354
Authors: Milena Girotti; Samantha M Adler; Sarah E Bulin; Elizabeth A Fucich; Denisse Paredes; David A Morilak Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2017-07-06 Impact factor: 5.067
Authors: Tessa Barkan; Michael Hoerger; Autumn M Gallegos; Nicholas A Turiano; Paul R Duberstein; Jan A Moynihan Journal: J Altern Complement Med Date: 2016-03-31 Impact factor: 2.579
Authors: Elizabeth L Addington; Shireen Javandel; Victor De Gruttola; Robert Paul; Benedetta Milanini; Beau M Ances; Judith T Moskowitz; Victor Valcour Journal: Contemp Clin Trials Date: 2020-09-15 Impact factor: 2.226
Authors: Allison Hicks; Kala Phillips; Chelsea Siwik; Paul Salmon; Irene Litvan; Megan E Jablonski; J Vincent Filoteo; Karen Kayser; Sandra E Sephton Journal: Qual Life Res Date: 2019-06-14 Impact factor: 4.147